Enabling large-volume/high-dose subcutaneous autoinjections with cartridge-based technologies
In the latest issue of ONdrug Delivery magazine, Michael McGowan, Senior Director of Market Intelligence at SHL Medical, examines the emerging interest within the pharmaceutical industry for autoinjectors that are capable of delivering higher injection volumes into the subcutaneous space.
The article initially discusses how autoinjector products have been designed historically with pre-filled syringes as the primary container. In the context of large-volume, high-dose autoinjector combination product development, the article then outlines some of the potential benefits of cartridge-based 3.0 mL and 5.0 mL autoinjectors as well as their suitability to address the needs of the biotech industry and patients in this evolving market segment. In May 2022, SHL Medical launched the Maggie 5.0 autoinjector. Incorporating the market-proven Needle Isolation Technology (NIT®) cannula unit, the Maggie 5.0 is a two-step autoinjector that eliminates the need for users to manually attach the needle prior to injection. Moreover, NIT® is available in a range of gauges and lengths not readily available with prefilled syringes, allowing for full control and customization of the pre-attached cannula dimensions.
Access the article here to learn more about SHL’s recently expanded drug delivery solutions for large-volume/high-dose drug delivery, now including the Maggie 5.0 autoinjector.
